HERO-MOTOCORP
1.7.2024 16:24:30 CEST | Business Wire | Press release
Hero MotoCorp, the world's largest motorcycle and scooter manufacturer, is paying tribute to its visionary Founder Chairman, Dr. Brijmohan Lall Munjal, with the collector's edition motorcycle, 'The Centennial.'
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240701062737/en/
The Centennial (Photo: Business Wire)
"Dr. Brijmohan Lall Munjal, my father and Founder Chairman of Hero MotoCorp, inspired billions worldwide. His vision transformed the landscape of the Indian automotive industry, and the Indian industry, leaving behind a legacy of ingenuity, innovation, courage and integrity. For him, business transcended profit - it was about people, both the individual and the community.
"As we celebrate the completion of one year of his centennial anniversary, I am overwhelmed and proud to introduce ‘The Centennial’ - a marvel of engineering crafted in honour of his legacy. ‘The Centennial’ is not merely a landmark motorcycle but a memoir, written in steel and carbon fibre. This magnificent machine's design, engineering and technology all reflect the indelible mark of our inspiring Founder.
"His inclusive vision embraced everyone in the Hero community – our customers, employees, dealers, partners, suppliers, and other stakeholders. Over these 100 days, we celebrate the man who started it all. I invite everyone to join us in honouring Dr. Brijmohan Lall Munjal on his 101st birth anniversary."
Dr. Pawan Munjal
Executive Chairman
Hero MotoCorp
'The Centennial' was conceptualised, designed and developed by the global experts at the Hero Centre for Innovation and Technology (CIT) in India and the Hero Tech Centre in Germany (TCG). This masterpiece reflects the company's commitment to innovation and excellence. With only 100 meticulously handcrafted units, it embodies premium performance and craftsmanship.
In honour of Dr. Brijmohan Lall Munjal's 101st birth anniversary, the company will auction these bikes to its employees, associates, business partners, and stakeholders. The proceeds from the contributions will be utilised for the society's greater good, reflecting the Founder's enduring value of giving back to the community.
Deliveries of ‘The Centennial’ will begin in September 2024.
Additionally, driven by its commitment to inclusivity and sustainability, the company is celebrating 100 days of customer and employee engagements across its facilities and dealer network, including its Global markets. During this period, customers who buy any Hero motorcycle or scooter will have the unique opportunity to receive 100% cashback on their purchase. This offer is available for a limited number of 100 vehicles. Further details are available on the company website and social media platforms.
Hero MotoCorp will also be inviting its customers to partake in the ‘My Hero, My Story’ campaign, where they can share anecdotes showcasing their unique bond and journey with the brand. A distinguished panel of experts from diverse backgrounds will carefully evaluate the submissions, and the top entries will be rewarded with the coveted ‘The Centennial.’
The Centennial
‘The Centennial’ stands out with its exceptional craftsmanship, carbon fibre and milled aluminium usage, and meticulous engineering.
Its distinctive elements include a lightweight aluminium swingarm for an enhanced riding experience and newly designed carbon fibre body panels for sleek aesthetics and structural rigidity. ‘The Centennial’ features are specially developed, machined, and anodised, including handlebars, handlebar mounts, triple clamps, and rear-set foot pegs.
Delivering impressive performance and agility, the bike is equipped with a gas-charged, fully adjustable mono-shock from Wilbers and a 43-mm upside-down front suspension with damping adjustment.
A distinct, deep exhaust note emanates from the top-of-the-line carbon fibre and titanium exhaust system by Akrapovic, which is specially tuned for peak performance and integrates seamlessly with the bike.
The solo seat with a carbon fibre seat cowl and milled aluminium special edition numbered badging on the side covers add to the bike's uniqueness and exclusivity. Attention to detail is evident in the diamond-cut alloy wheels and the engine and frame's paint scheme, which enhance the motorcycle's visual appeal.
With a low kerb weight of 158 kg, ‘The Centennial’ is exceptionally light, offering superior throttle response and improved handling and braking performance.
For more information, please visit - https://www.heromotocorp.com/en-in/the-centennial.html
For more information on Hero MotoCorp:
https://www.heromotocorp.com/en-in/
https://www.facebook.com/HeroMotoCorpIndia
https://twitter.com/HeroMotoCorp
https://www.instagram.com/heromotocorp/
https://www.youtube.com/c/HeroMotoCorp
https://www.linkedin.com/company/heromotocorp/mycompany/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240701062737/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom